You are here:

lacosamide (Vimpat)

Advice

Following a full submission lacosamide (Vimpat) is accepted for restricted use within NHS Scotland as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older.

The proportion of responders was significantly greater with adjunctive lacosamide treatment compared to placebo. Lacosamide use is restricted to patients with refractory epilepsy and treatment should be initiated by physicians who have appropriate experience in the treatment of epilepsy

Drug Details

Drug Name: lacosamide (Vimpat)
SMC Drug ID: 532/09
Manufacturer: UCB Pharma Ltd
Indication: Adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years or older
BNF Category:
Sub Category: 4.8 Antiepileptic drugs
Submission Type: Full submission
Status: Restricted
Date Advice Published: 9 February 2009

Back